Earnings● Neutral
Halozyme (HALO) Reports Q2 2026 Earnings, CEO Comments on Business
Halozyme reported Q2 2026 financial results after market close. CEO Helen Torley and CFO Darren Snellgrove discussed quarterly performance and business outlook.
Continue with
AlphaScala Research Snapshot
Live stock context for companies directly referenced in this story
Alpha Score of 45 reflects weak overall profile with moderate momentum, poor value, moderate quality, strong sentiment.
Alpha Score
46
Weak
This panel uses AlphaScala-native stock data — proprietary scoring and live snapshots.
Halozyme Therapeutics reported its second-quarter 2026 financial results after the market closed Thursday. The company hosted a conference call at 4:30 p.m. Eastern. CEO Helen Torley and CFO Darren Snellgrove led the discussion. They covered the quarter's performance and gave a business update.
The call included forward-looking statements. The company referred investors to its SEC filings for a full list of risks. Halozyme also discussed non-GAAP financial measures. A reconciliation to GAAP figures is available in the earnings release and slide presentation.
Tram Bui, head of investor relations, opened the call. She noted the press release and supplementary slides are on the company's website. Torley then provided the business update. Snellgrove reviewed the financials and outlook.
The full financial results are in the press release issued after the close.
How this story was producedLast reviewed Aug 6, 2026
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.
Explore More
More from AlphaScala
Trading Q&A
How to start trading stocks as a beginner?
What is the S&P 500 index?
What is an ETF and how does it work?
What is a hedge fund?